Publications
Find an abstract and a link to most of the publications produced by Nordic Bioscience
Evidence indicate that the brain-specific protein, brevican, is proteolytically cleaved during neurodegeneration, hence positioning fragments of brevican as potential blood biomarkers of neurodegenerative diseases, such as dementia. We aimed to develop two assays capable of detecting the brevican N-...
BACKGROUND: Truncated tau appears to be specifically related to disease pathology and recent studies have shown the presence and elevation of several truncated tau species in Cerebrospinal fluid (CSF) of subjects with Alzheimer\u0027s disease (AD); however, the relevance of truncated Tau measurement...
April 11, 2018
Journal:
PLoS One
Author:
Neergaard JS, Dragsbæk K, Christiansen C, Karsdal MA, Brix S, Henriksen K
The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patien...
November 18, 2016
Journal:
Alzheimers Dement
Author:
O'Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, Lewczuk P, Posner H, Hall J, Johnson L, Fong YL, Luthman J, Jeromin A, Batrla-Utermann R, Villarreal A, Britton G, Snyder PJ, Henriksen K, Grammas P, Gupta V, Martins R, Hampel H
Since the first evidence of a decline in dementia incidence was reported in 2011, the focus on modifiable risk factors has increased. The possibility of risk factor intervention as a prevention strategy has been widely discussed; however, further evidence in relation to risk factors is still needed....
March 1, 2016
Journal:
Medicine (Baltimore)
Author:
Neergaard JS, Dragsbæk K, Hansen HB, Henriksen K, Christiansen C, Karsdal MA
Differential diagnosis of AD is still a challenge due to overlapping features with other types of dementia. Biomarkers for the differential diagnosis of AD can improve the diagnostic value of the disease and ensure an appropriate treatment of patients. The aim of this study was to evaluate the poten...
July 10, 2015
Journal:
Curr Alzheimer Res
Author:
Inekci D, Henriksen K, Linemann T, Karsdal MA, Habib A, Bisgaard C, Eriksen FB, Vilholm OJ
Enzyme-generated fragments of tau have been linked to neuronal death and may serve as serum biomarkers of cognitive loss. Two competitive ELISAs detecting an ADAM10-generated fragment (Tau-A) or a caspase-3-generated fragment (Tau-C) were measured in baseline serum samples from patients with mild to...
June 11, 2015
Journal:
Int J Alzheimers Dis
Author:
Henriksen K, Byrjalsen I, Christiansen C, Karsdal MA
The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebr...
May 11, 2015
Journal:
Alzheimers Dement
Author:
O'Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, Bazenet C, Soares H, Lovestone S, Hampel H, Blennow K, Graff-Radford N, Laske C, Breteler M, Shaw L, Trojanowski JQ, Schupf N, Rissman RA, Fagan AM, Oberoi P, Umek R, Weiner MW, Grammas P, Posner H, Martins R, Carrillo MC, Montine TJ
The diagnosis of dementia is challenging and early stages are rarely detected limiting the possibilities for early intervention. Another challenge is the overlap in the clinical features across the different dementia types leading to difficulties in the differential diagnosis. Identifying biomarkers...
Treatment of Alzheimer's disease (AD) is significantly hampered by the lack of easily accessible biomarkers that can detect disease presence and predict disease risk reliably. Fluid biomarkers of AD currently provide indications of disease stage; however, they are not robust predictors of disease pr...
January 10, 2014
Journal:
Alzheimers Dement
Author:
Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lönneborg A, Wyss-Coray T, Soares H, Bazanet C, Sjögren M, Hu W, Lovestone S, Karsdal MA, Weiner MW, Blood-Based Biomarker Interest Group
(AD) is a devastating neurological disease characterized by pathological proteolytic cleavage of tau protein, which appears to initiate death of the neurons. The objective of this study was to investigate whether a proteolytic fragment of the tau protein could serve as blood-based biomarker of cogni...
May 22, 2013
Journal:
PLoS One
Author:
Henriksen K, Wang Y, Sørensen MG, Barascuk N, Suhy J, Pedersen JT, Duffin KL, Dean RA, Pajak M, Christiansen C, Zheng Q, Karsdal MA
Drug development for dementias is significantly hampered by the lack of easily accessible biomarkers. Fluid biomarkers of dementias provide indications of disease stage, but have little prognostic value, cannot detect early pathological changes, and can only be measured in CSF (cerebrospinal fluid) ...
December 12, 2012
Journal:
Int J Alzheimers Dis
Author:
Wang Y, Sørensen MG, Zheng Q, Zhang C, Karsdal MA, Henriksen K
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
